HOME >> BIOLOGY >> NEWS
Other highlights in the Aug. 7 JNCI

Vitamins and Minerals Showed Little Benefit on Liver Cancer Death Rates

Taking vitamins and minerals did not reduce liver cancer death rates in a study conducted by the National Cancer Institute and the Chinese Academy of Medical Sciences.

Liver cancer is a common cancer with a high death rate. New prevention strategies are needed to reduce the number of deaths from the disease.

Chen-Xu Qu, M.D., and colleagues conducted a randomized clinical trial that examined whether four vitamin-mineral supplement combinations could effect the liver cancer death rate in a Chinese population that was deficient in many vitamins and minerals. Study participants took two or four of the following combinations: retinol and zinc; riboflavin and niacin; ascorbic acid and molybdenum; beta-carotene, alpha-tocopherol, and selenium; or placebo pills.

After 5.25 years, none of the vitamin-mineral combinations caused a statistically significant reduction in liver cancer deaths overall. However, some combinations reduced risk in subgroups defined by age, sex, and alcohol consumption. These subgroup analyses need to be interpreted with caution, the authors write.

Contact: National Cancer Institute press office, ncipressofficers@mail.nih.gov, (301) 496-6641


Prior Testicular Cancer Diagnosis Has Little Impact on Second Cancer Survival

Testicular cancer survivors diagnosed with a second cancer had mortality rates similar to men diagnosed with a first cancer, except among some diagnosed with testicular cancer between 1973 and 1979.

Most testicular cancer patients are cured, but survivors are at a higher risk for second cancers later in life. There is little data on mortality rates of testicular cancer survivors with a second cancer.

Catherine Schairer, Ph.D., of the National Cancer Institute in Bethesda, Md., and colleagues co
'"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
7-Aug-2007


Page: 1 2 3

Related biology news :

1. Other highlights in the July 24 JNCI
2. Other highlights from the July 10 JNCI
3. Other highlights in JNCI, June 26
4. Other highlights in JNCI, June 12
5. Other highlights from the June 6 JNCI
6. Other highlights in the May 16 JNCI
7. Other highlights from the April 18 Journal of the National Cancer Institute
8. Other highlights from the March 21 JNCI
9. Other highlights in the March 7 JNCI
10. Other highlights in the Feb. 21 JNCI
11. Other highlights in the Jan. 17 JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... solutions for drugs, biologics, cell and gene therapies, and consumer health products, today ... PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September ...
(Date:8/21/2020)... ... August 19, 2020 , ... “How can we ... dedicated to Salivary Bioscience for more than twenty years. Together with Douglas Granger, ... " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications ," and Steven ...
(Date:8/12/2020)... , ... August 12, 2020 , ... ... monitoring systems that are ideal for public health agencies of all sizes. With ... diseases and helping at-risk individuals find appropriate health care, Mosio helps public health ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
(Date:7/1/2020)... , ... June 30, 2020 ... ... tissue data insights, today announced that the launch of a new ... with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is a ...
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. (“Lumeda”), ... announced the company has entered a license agreement with Roswell Park Comprehensive Cancer ... exclusive rights to Roswell Park intellectual property surrounding a novel medical device and ...
Breaking Biology Technology:
Cached News: